|
Jan 16
|
Sector Update: Health Care Stocks Rise Late Afternoon
|
|
Jan 16
|
Outlook Therapeutics Shares Fall After Reporting Trial Results for ONS-5010 in Wet AMD
|
|
Jan 16
|
Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug
|
|
Jan 16
|
Outlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial
|
|
Dec 30
|
Outlook Therapeutics Stock Surges on Positive Outlook Despite Loss
|
|
Sep 13
|
Outlook Therapeutics® Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series
|
|
Jul 30
|
Outlook Therapeutics® to Present at the BTIG Virtual Biotechnology Conference 2024
|
|
Jun 19
|
Outlook Therapeutics, Inc.'s (NASDAQ:OTLK) largest shareholders are individual investors with 31% ownership, private equity firms own 31%
|
|
May 15
|
Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update
|
|
May 13
|
Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD
|
|
May 9
|
Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and Webcast
|
|
May 2
|
Outlook Therapeutics® to Present at the Retina World Congress 2024
|
|
Apr 29
|
Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase
|
|
Apr 26
|
Marriott Vacations, Carrols Restaurant Group, and More Stocks See Action From Activist Investors
|
|
Apr 15
|
Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million
|
|
Apr 15
|
Biotech on a Budget: 7 Stocks Under $10 With Huge Potential
|
|
Jan 31
|
Outlook Therapeutics® Doses First Subject in NORSE EIGHT
|
|
Dec 22
|
Outlook Therapeutics® Reports Financial Results for Fiscal Year 2023 and Reiterates ONS-5010 Clinical and Regulatory Path Forward in the U.S. and EU
|
|
Dec 19
|
Outlook Therapeutics® Submits Special Protocol Assessment (SPA) to FDA for Non-Inferiority Study of ONS-5010
|
|
Dec 6
|
Outlook Therapeutics® Announces Strategic Organizational Realignment
|